My WebLink
|
Help
|
About
|
Sign Out
Home
Browse
Search
Correspondence - Non Agenda
Clerk
>
Agenda Packets / Staff Reports
>
City Council (2004 - Present)
>
2025
>
10/07/2025 Regular & HA
>
Correspondence - Non Agenda
Metadata
Thumbnails
Annotations
Entry Properties
Last modified
11/13/2025 5:28:21 PM
Creation date
10/1/2025 10:00:30 AM
Metadata
Fields
Template:
City Clerk
Date
10/7/2025
Jump to thumbnail
< previous set
next set >
There are no annotations on this page.
Document management portal powered by Laserfiche WebLink 9 © 1998-2015
Laserfiche.
All rights reserved.
/
627
PDF
Print
Pages to print
Enter page numbers and/or page ranges separated by commas. For example, 1,3,5-12.
After downloading, print the document using a PDF reader (e.g. Adobe Reader).
View images
View plain text
Becerra, Alexis <br /> From: Jackie Angel Investor < <br /> Sent: Friday, October 3, 2025 7:38 PM <br /> To: eComment <br /> Cc: Vazquez, Benjamin <br /> Subject: Information for the following EXISTING LITIGATION <br /> Attention: This email originated from outside of City of Santa Ana.Use caution when opening attachments or links. <br /> NOTICE OF CANCELLATION <br /> Personnel Board Regular Meeting <br /> NOTICE IS HEREBY GIVEN that the Regular Meeting of the Personnel Board for September 25, 2025, <br /> is canceled. <br /> In June 2025, a $7.4 billion settlement was approved by 50 states and other territories. for the following <br /> EXISTING LITIGATION, City of Santa Ana involvement - FYI. <br /> D. In re: Purdue Pharma L.P. et al., United States Bankruptcy Court (S.D. NY) Case No. 19-23649 (SHL) <br /> E. In re National Prescription Opiate Litigation, United States District Court Case No. 1:17-and-2804 (MDL No. <br /> 2804) <br /> Purdue Pharma L.P. v. Commonwealth of Massachusetts was a landmark case where the state of <br /> Massachusetts sued Purdue Pharma for allegedly deceiving the public about the risks of its opioid OxyContin, <br /> leading to illness and death within the state. The lawsuit was part of a larger national effort to hold Purdue <br /> and the Sackler family accountable for their role in the opioid epidemic, but it became entangled in the <br /> complex legal and financial battles surrounding Purdue's bankruptcy proceedings and the Sacklers' efforts to <br /> seek protection from further lawsuits. <br /> Key Aspects of the Case: <br /> • Allegations: The Commonwealth of Massachusetts alleged that Purdue Pharma executives engaged in <br /> deceptive marketing practices by making false representations about OxyContin's addictive properties, leading <br /> to increased opioid use, overdose, and death in Massachusetts. <br /> • Settlements: The case was part of a broader push for a large settlement with Purdue Pharma and the Sackler <br /> family to fund opioid treatment and prevention programs across the country. In June 2025, a $7.4 billion <br /> settlement was approved by 50 states and other territories. <br /> https://santa-ana.primegov.com/Portal/Meeting?meetingTemplateId=23973 <br /> 1 <br />
The URL can be used to link to this page
Your browser does not support the video tag.